B Schaeffer, MD
Facial Plastic Surgery · New Hyde Park, NYNPI 1336129550
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 269 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations.
Across 269 payments — averaging $30.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$2K
- Sanofi$1K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Intersect ENT, Inc.$453
- Inspire Medical Systems, Inc.$290
- plus $2K from 26 others
Across 30 payments — averaging $2747.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$57K
- Optinose US, Inc.$23K
- Genentech, Inc.$1K
What the payments were for
- Food & beverage$8,243100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 47 | $1,740 |
| Sanofi | 49 | $1,477 |
| GSK | 52 | $1,325 |
| Regeneron Healthcare Solutions, Inc. | 56 | $1,141 |
| Intersect ENT, Inc. | 4 | $453 |
| Inspire Medical Systems, Inc. | 9 | $290 |
| Aerin Medical Inc. | 1 | $215 |
| Blueprint Medicines Corporation | 5 | $176 |
| Stryker | 4 | $175 |
| Neurent Medical Limited | 1 | $172 |
| Genentech USA, Inc. | 1 | $150 |
| Hikma Pharmaceuticals USA | 8 | $137 |
| Arrinex, Inc. | 1 | $120 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $86 |
| Novartis | 3 | $81 |
| Acclarent, Inc | 2 | $62 |
| Alk-abello, Inc | 5 | $59 |
| Smith+Nephew | 2 | $53 |
| Pfizer | 2 | $44 |
| Merck | 2 | $40 |
| Integra Lifesciences Corporation | 1 | $33 |
| Acelrx Pharmaceuticals, Inc. | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Aytu Biopharma, Inc. | 1 | $22 |
| Photonicare Inc | 1 | $22 |
| Octapharma USA, Inc. | 1 | $20 |
| Circassia Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xhance$866
- DUPIXENT$500
- SINUVA$285
- NUCALA$250
- Vivaer RF Stylus$215
- NEUROMARK Device$172
- NEUROMARK Radiofrequency Console$172
- XOLAIR$150
- PROPEL$149
- Inspire$121
- CLARIFIX$120
How this compares
$8,243 in reported general payments places this provider in the 85th percentile of 48 facial plastic surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XhanceFluticasone Propionate | 15 | $15,631 |
| Fluticasone Propionate | 415 | $10,381 |
| CefuroximeCefuroxime Axetil | 149 | $1,920 |
| Azelastine Hcl | 52 | $1,672 |
| Ofloxacin | 72 | $1,614 |
| Ipratropium Bromide | 20 | $1,223 |
| Nystatin | 31 | $1,061 |
| Mometasone Furoate | 53 | $1,020 |
| Famotidine | 164 | $744 |
| Omeprazole | 90 | $598 |
| Mupirocin | 54 | $353 |
| Doxycycline Monohydrate | 41 | $350 |
| Clindamycin Hcl | 31 | $306 |
| Prednisone | 112 | $261 |
| Montelukast Sodium | 18 | $228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $1,740 | $15,63115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 48 facial plastic surgery providers in New York.
Other facial plastic surgery in New Hyde Park
- Ran RubinsteinNewburgh$330K
- Joshua RosenbergNew York$61K
- Allison PontiusNew York$55K
- Michael CohenSyosset$10K
- Daniel LeeLatham$10K
- Lesley RabachNew York$9K
- Michael BergsteinTarrytown$8K
- Daniel DemeshNew York$6K
- Steven PearlmanNew York$6K
- Yael HalaasNew York$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.